WHAT'S NEXT? If you suffered a loss in Inspire Medical Systems, Inc. during the relevant time frame, you have until January 5, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NEW YORK, Dec. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: ...

Industry Overview - The global Gynecological Devices market is expanding due to the higher prevalence of diseases such as PCOS, uterine fibroids, and cervical cancer, along with continued innovation in minimally invasive procedures and increased awareness of women's health and reproductive care. The market is projected to grow at a CAGR of 8.25% from 2025 to 2034, with North America expected to account for the highest revenue share [1] Company Performance - Hologic's GYN Surgical division reported revenues of $679.8 million in fiscal 2025, reflecting a 6% increase from fiscal 2024. This growth has been driven by a combination of internal innovation and product additions through mergers and acquisitions [2][8] - The Myosure devices are experiencing stronger international sales compared to the United States, indicating significant untapped demand for minimally invasive treatments of uterine polyps and fibroids. NovaSure is also seeing rapid adoption overseas, particularly in Europe, supported by improved reimbursement dynamics [3] - Hologic has expanded its fibroid treatment portfolio through acquisitions, including Acessa Health in 2020, Bolder Surgical, and Gynesonics in fiscal 2025, positioning the GYN Surgical segment for sustained long-term growth [4][8] Market Position and Valuation - Hologic's stock has risen 14.6% over the past six months, slightly below the industry's growth of 14.8%. The company is currently trading at a forward one-year price-to-sales (P/S) ratio of 3.83X, which is lower than the industry average of 4.41X [7][9]

Core Insights - Bruker Corporation (BRKR) is positioned for growth due to strong prospects in its CALID group and BSI Nano segment, despite facing potential macroeconomic challenges and funding constraints [1][7]. Group 1: Financial Performance - Over the past year, BRKR stock has declined by 17.5%, underperforming the S&P 500's 16.7% rise and slightly better than the industry's 18.8% decline [2][7]. - The company has a market capitalization of $7.31 billion and an earnings yield of 3.9%, which is higher than the industry's 3.3% yield [2]. - In the trailing four quarters, Bruker surpassed earnings estimates three times, with an average surprise of 9.2% [2]. Group 2: Growth Drivers - The CALID group generated $879 million in revenue year-to-date through September 2025, driven by strong demand in microbiology and infectious disease diagnostics [3]. - Innovations such as the Fourier 80 multinuclear benchtop FT-NMR spectrometer and the MOVE-T liquid dairy analyzer have been introduced, enhancing Bruker's product offerings [4]. - The BSI Nano group reported revenues of $775 million year-to-date, supported by contributions from Spatial Biology and strength in biopharma markets [8]. Group 3: Strategic Developments - Bruker acquired the majority of NanoString Technologies' assets and formed the Spatial Biology division, enhancing its capabilities in the life sciences [5]. - The acquisition of Chemspeed Technologies AG in 2024 has accelerated Bruker's entry into lab automation and digitalization [9]. - The company has made significant investments in RECIPE Chemicals + Instruments GmbH to enhance its small molecule clinical diagnostic capabilities [4]. Group 4: Challenges - Bruker faces macroeconomic challenges, including geopolitical tensions and new U.S. tariffs, which have adversely affected its business operations [11]. - Funding constraints in U.S. academic research have led to reduced demand for high-end research instrumentation, impacting the company's revenue [12]. - Supply chain risks, inflation, and currency volatility continue to pose challenges, leading to increased costs and pressure on profitability [11].

Core Insights - Hardman Johnston Global Advisors reported underperformance in its portfolio for Q3 2025, with a return of 5.02% net of fees, compared to 7.62% for the MSCI AC World Net Index [1] Company Overview - Boston Scientific Corporation (NYSE:BSX) is highlighted as a key stock in the investor letter, operating in the MedSurg and Cardiovascular segments of the medical device industry [2] - As of December 24, 2025, Boston Scientific's stock closed at $96.13 per share, with a market capitalization of $142.51 billion [2] Performance Analysis - Boston Scientific experienced a one-month return of -4.78% but gained 5.56% over the last 52 weeks [2] - The company was identified as a significant driver of underperformance within the healthcare sector, alongside Vertex Pharmaceuticals [3] Market Context - The Trump administration's Section 232 tariff investigation into medical devices has increased macroeconomic uncertainty, but Boston Scientific is well-positioned to manage potential tariffs due to its diverse supply chain and increased U.S. manufacturing footprint post-COVID [3] - The company has strong pricing power and has largely mitigated tariff impacts thus far [3] - The market is witnessing a rotation from medical devices to pharmaceuticals/biotech, influenced by recent deals such as the one between Pfizer and the Trump administration [3] Growth Prospects - Boston Scientific's diversified growth profile across various franchises, including cardiology, electrophysiology, endoscopy, and urology, supports a favorable outlook [3] - The introduction of Farapulse, a pulsed-field ablation technology, is expected to drive significant growth in the electrophysiology segment [3] - Management has set new long-term targets of 10% organic revenue growth, 50 basis points of annual margin expansion, and double-digit EPS growth through 2028, with a strong track record of exceeding previous targets [3]

New York, New York--(Newsfile Corp. - December 26, 2025) - Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfa ...

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and certain senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, significantly below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Insights - Intuitive Surgical's (ISRG) third-quarter results show a 20% year-over-year increase in combined da Vinci and Ion procedures, raising questions about the sustainability of this growth rate [2][6] Company Performance - da Vinci procedures grew by 19%, while Ion volumes surged by 52%, with growth observed across various surgical fields including general surgery, gynecology, and international markets [3] - The introduction of da Vinci 5 has led to higher utilization rates compared to previous Xi systems, with U.S. utilization turning positive after being flat earlier in the year [3] - Management noted that some elective procedures may have been advanced due to uncertainties around Medicare funding, although this has not been confirmed by third-party data [4] - Bariatric procedures are declining at high single-digit rates due to the adoption of GLP-1 therapies, highlighting that not all surgical demand is immune to therapeutic changes [5] Market Dynamics - International growth was slightly aided by holiday timing shifts, contributing approximately one percentage point to growth [4] - Hospital budget constraints, particularly outside the U.S., and macro health policy changes could impact future capital and utilization momentum [5] Valuation and Estimates - ISRG's shares have increased by 8.1% over the past six months, compared to a 14.8% rise in the industry [12] - The company trades at a forward price-to-earnings ratio of 60.4, which is above the industry average but below its five-year median of 71.52 [13] - The Zacks Consensus Estimate for ISRG's 2025 earnings suggests a 17.9% increase from the previous year [15]

Core Insights - Abbott Laboratories (ABT) is valued at a market cap of $217 billion and operates in the healthcare sector, focusing on medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals [1] Financial Performance - Analysts expect ABT to report a profit of $1.50 per share for fiscal Q4 2025, reflecting an 11.9% increase from $1.34 per share in the same quarter last year [2] - For the current fiscal year ending in December, ABT is projected to report a profit of $5.15 per share, up 10.3% from $4.67 per share in fiscal 2024, with an expected EPS growth of 9.9% year-over-year to $5.66 in fiscal 2026 [3] Stock Performance - Over the past 52 weeks, ABT shares have gained 8.8%, underperforming the S&P 500 Index's 14.8% return and the State Street Health Care Select Sector SPDR ETF's 11.8% increase [4] - On October 15, ABT shares fell by 2.9% following mixed Q3 earnings results, with net sales increasing 6.9% year-over-year to $11.4 billion but missing consensus estimates due to a decline in the diagnostic products segment [5] Analyst Ratings - Wall Street analysts maintain a "Strong Buy" rating for ABT, with 19 out of 27 analysts recommending "Strong Buy," two suggesting "Moderate Buy," and six indicating "Hold." The mean price target for ABT is $146.69, suggesting a 17.5% potential upside from current levels [6]

Company Overview - electroCore is a publicly traded neuromodulation company listed on NASDAQ under the symbol ECOR, focusing on non-invasive vagus nerve stimulation devices [3] - The company was founded in 2006 and has developed into a multi-indication business with 7 FDA authorizations for headache treatments [5] Product and Service Channels - The company operates across three main channels: prescription medical devices for headache and migraine, the Truvaga direct-to-consumer wellness brand, and a specialized military and government division featuring the ruggedized TAC-STIM product [4] - The nVNS platform delivers a two-minute therapy session aimed at rebalancing the autonomic nervous system [3] Market and Clientele - electroCore serves major customers including the U.S. Department of Veterans Affairs and the U.K.'s National Health Service, indicating a strong foothold in both governmental and healthcare sectors [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on January 5, 2026 [1]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 5, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements since 2013 [4]. Group 3: Case Background - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and readiness for launch, leading to investor losses when the truth was revealed [5].